OBJECTIVES: Deep Brain Stimulation (DBS) for the treatment of advanced Parkinson’s Disease (PD) is a therapy supported with high level evidence, however no direct comparative studies exist of DBS against other therapy options, such as continued subcutaneous apomorphine infusion (CSAI) exists. The objective of this study was to evaluate the 5-year cost profiles of two therapies for advanced PD, DBS and CSAI, from a UK payer perspective. METHODS: A Markov model, previously used to model cost-effectiveness of DBS+BMT vs BMT alone (Eggington 2013), served to evaluate the cost profile of DBS and CSAI over five-years. Equal efficacy of the two therapies was assumed. The cost analysis covered: device acquisition, implantation, adverse event management, concomitant drug use, device replacements and follow-up. Cost data were taken from UK national tariffs, combined with device/drug price lists and data from previous economic studies of interventions for PD. Disease-related inputs were based on recent studies of DBS and CSAI in patients with advanced PD, plus long-term data from the literature. Costs were discounted at 3.5% per annum. RESULTS: Total discounted costs over 5 years were £69,566 and £80,843 for DBS and CSAI, respectively, leading to cost savings of £11,277 of DBS compared to CSAI over 5 years. DBS is cost saving compared to CSAI from 3 years onwards, with the initial costs of DBS device acquisition shown to be offset by the on-going provision of CSAI. CONCLUSIONS: The results indicate that DBS requires less healthcare resources than CSAI over five-years. Comparative clinical data are needed to formally assess the relative cost-effectiveness of the two interventions.